A Randomized Phase 3 Study of Vincristine Dactinomycin Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI Torisel NSC# 683864 IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: rhabdomyosarcoma
  • Age: Between 0 - 40 Years
  • Gender: Male or Female

Inclusion Criteria
Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based upon institutional histopathologic classification
Patients must have sufficient tissue available for the required biology study
Adequate bone marrow function
Adequate renal function
Adequate liver function
Exclusion Criteria
Patients who have previously received TORI, another mTOR inhibitor, or any other investigational agent
Patients who have received any chemotherapy (excludign steroids) and/or radiation therapy prior to this enrollment
Patients with uncontrolled hyperglycemia
Patients with hyperlipidemia
Sexually active patient of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for at least 3 months after treatment is completed if sexually active with reproductive potential
Pregnant or breastfeeding (lactating)

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176